Jeena Sikho Lifecare Publishes Case Studies on Ayurvedic CKD Treatment
Jeena Sikho Lifecare Limited published case studies on Ayurvedic treatment for Chronic Kidney Disease (CKD). A case study on a 56-year-old patient showed improvements in blood urea, serum creatinine, and uric acid levels. The company highlights its commitment to Ayurvedic research and evidence-based practices.
The announcement pertains to research publications and case studies, which are generally considered positive for brand image and long-term credibility but do not represent immediate material financial impact or significant business development.
The announcement details positive research outcomes and publications that showcase the company's expertise and commitment to advancing Ayurvedic medicine, particularly in managing chronic diseases.
Jeena Sikho Lifecare Limited has announced the publication of three academic papers: two case studies and one case report, in the International Journal of Ayurveda and Herbal Research and the Journal of Applied Science and Education. These publications, co-authored by the company's Managing Director, Acharya Manish Grover, along with other medical professionals from the company, highlight the advancement of Ayurvedic research and the promotion of evidence-based clinical practices.
The case studies focus on the management of Chronic Kidney Disease (CKD) using Ayurvedic therapies. One study details a case of a 56-year-old male patient with Stage V CKD, hypertension, Type 2 Diabetes Mellitus, and Coronary Artery Disease. The integrated treatment, combining Ayurvedic medications with a disciplined intelligent person's (DIP) diet and lifestyle modifications, showed significant improvements. Key results included a reduction in blood urea from 230.86 mg/dL to 117.39 mg/dL, serum creatinine from 6.32 mg/dL to 5.17 mg/dL, and uric acid from 7.80 mg/dL to 6.36 mg/dL. Pedal edema decreased from grade 3 to grade 1, and severe weakness was alleviated.
The publications aim to reflect the company's commitment to evidence-based Ayurvedic practices and suggest the potential of Ayurveda as a complementary approach to managing complex conditions like CKD. The company emphasizes that while findings are promising, further larger randomized controlled trials are necessary to establish standardized treatment guidelines.
What to do with a filing like this
Jeena Sikho Lifecare Limited filed this with the NSE as a statutory disclosure, categorised under other company updates. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Jeena Sikho Lifecare Limited. Read the original for the full detail.